• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Tremfya SC Data Supports IV & SC Induction In Ulcerative Colitis

    PR NEWSWIRE

    Idorsia’s Jean-Paul Clozel retires as CEO; CRISPR nabs CMO from Sanofi

    ENDPTS

    Janssen Submits MAA to the EMA Seeking Approval of Erdafitinib

    GLOBENEWSWIRE

    Janssen Submits sNDA to the USFDA Seeking Full Approval of BALVERSA for MUC

    PR NEWSWIRE

    Janssen submits sBLA to FDA for NSCLC combination therapy

    PHARMACEUTICAL TECHNOLOGY

    Janssen Submits sBLA to FDA Seeking Approval of RYBREVANT for NSCLC

    PR NEWSWIRE

    J&J`s Janssen to close part of its vaccine division

    REUTERS

    EC Approves Reduced Dosing Frequency for Janssen™s Bispecific Antibody TECVAYLI

    GLOBENEWSWIRE

    Janssen`s infectious disease partners left in the lurch

    FIERCE BIOTECH

    Janssen Receives Positive CHMP Opinions for Antibodies TALVEY and TECVAYLI

    GLOBENEWSWIRE

    Janssen`s merged infectious disease and vax pipeline is halved

    FIERCE BIOTECH

    J&J to move oral IL-23 drug into late-stage studies for plaque psoriasis

    PR NEWSWIRE

    New Phase 2 Data Demonstrate Benefit of Nipocalimab for Pregnant Individuals

    PR NEWSWIRE

    New PII Data Demonstrate Benefit of Nipocalimab for Pregnant Individuals

    GLOBENEWSWIRE

    MRCT Center and Medable Launch First, Comprehensive IRB/EC Review

    BUSINESSWIRE

    Janssen Submits sBLA to U.S. FDA Seeking Approval of CARVYKTI

    PRESS RELEASE

    Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

    GLOBENEWSWIRE

    Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached

    PR NEWSWIRE

    Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma

    GLOBENEWSWIRE

    Janssen to Highlight Advances and Commitment to Transform Cancer Care at ASCO

    PRESS RELEASE

    Protagonist Reports Positive Results from Ph1 &Preclinical Studies Oral JNJ-2113

    PR NEWSWIRE

    Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200

    PR NEWSWIRE

    Janssen Provides Portfolio Update

    PR NEWSWIRE

    TREMFYA Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis

    PR NEWSWIRE

    TREMFYA Demonstrates a Differentiated Binding Mechanism from Risankizumab

    PR NEWSWIRE

    Janssen Data at ASCO Support Ambition to Transform Treatment of Prostate Cancer

    PR NEWSWIRE

    Janssen Reports Positive Phase 2 Results for Nipocalimab in Pregnant Individuals

    PRESS RELEASE

    Janssen and Eli Lilly collaboration to address lack of pediatric therapies

    INDIAN PHARMA POST

    Janssen submits marketing application for talquetamab

    PHARMA TIMES

    Janssen Submits Marketing Authorisation to the EMA Seeking Approval Talquetamab

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.